Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Stock Information for Alzamend Neuro Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Alzamend Neuro Inc.

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital
Alzamend Neuro Announces Reverse Stock Split

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.